Planet DDS vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud-native dental practice management including Denticon for DSOs and Apteryx XVWeb for cloud imaging. Irvine CA; founded 2003;
About
Planet DDS is an Irvine, California-based cloud-native dental software company that offers an integrated suite of tools for dental practices, DSOs, and dental imaging, with Denticon as its flagship cloud practice management system and Apteryx XVWeb as its cloud imaging platform. Founded in 2003, Planet DDS built Denticon as one of the first true multi-site, cloud-based dental practice management systems at a time when the market was dominated by legacy on-premise software. Denticon's multi-location architecture allows DSOs and group practices to manage enterprise-level functions—credentialing, reporting, fee schedule management, and patient record sharing across locations—from a centralized cloud platform rather than managing separate on-premise installations at each site.\n\nPlanet DDS has doubled down on the DSO market, where its cloud architecture offers significant operational advantages over legacy systems that require local servers, manual software updates, and location-by-location IT support. The company's acquisition of Apteryx, a dental imaging software business, extended its platform into digital radiography management, allowing practices to manage both clinical workflows and imaging through an integrated cloud environment. Planet DDS also acquired Legwork in 2021, a dental patient communication and marketing platform, adding patient engagement, online scheduling, and reputation management capabilities to its suite.\n\nThe DSO market has been growing rapidly as dental consolidation accelerates, and Planet DDS is positioned to benefit from practices migrating away from Dentrix and Eaglesoft to cloud-native platforms that can scale with multi-location growth. The company integrates with dental imaging sensors, intraoral cameras, and third-party lab management systems. Planet DDS competes with Carestream Dental, Curve Dental, and the Carestream/Apteryx imaging market alongside practice management leaders Dentrix and Eaglesoft, which are owned by Henry Schein.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.